Sana Biotechnology Inc
SANA
Company Profile
Business description
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Contact
188 East Blaine Street
Suite 400
SeattleWA98102
USAT: +1 206 701-7914
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
194
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,576.60 | 46.80 | 0.55% |
| CAC 40 | 7,853.47 | 16.68 | 0.21% |
| DAX 40 | 23,695.59 | 168.58 | 0.72% |
| Dow JONES (US) | 42,322.75 | 271.69 | 0.65% |
| FTSE 100 | 8,633.75 | 48.74 | 0.57% |
| HKSE | 23,262.80 | 190.36 | -0.81% |
| NASDAQ | 19,112.32 | 34.49 | -0.18% |
| Nikkei 225 | 37,734.00 | 21.51 | -0.06% |
| NZX 50 Index | 12,791.30 | 89.52 | -0.69% |
| S&P 500 | 5,916.93 | 24.35 | 0.41% |
| S&P/ASX 200 | 8,341.60 | 44.10 | 0.53% |
| SSE Composite Index | 3,363.32 | 17.50 | -0.52% |